A variant of the chemotherapy-associated erythrodysesthesia syndrome related to high-dose cyclophosphamide.
A 33-year-old woman with stage IIIA non-Hodgkin's lymphoma unresponsive to ten cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) developed a variant of the chemotherapy-associated erythrodysesthesia syndrome following high-dose cyclophosphamide and radiation in preparation for an autologous bone marrow transplant. The patient first complained of a new rash on her fingers and toes on day 6 after her first dose of cyclophosphamide. Unlike the previous case reports in which patients presented with a palmar-plantar erythema, this patient's rash occurred on the dorsal aspects of her hands and feet, and not on her palms and soles. After evaluation by a dermatologist she was diagnosed as having a variant of palmar-plantar erythema induced by cyclophosphamide.
Matsuyama
J R
JR
Department of Pharmacy, University of Washington Medical Center, Seattle 98195.
Kwok
K K
KK
D000328:Adult; D003520:Cyclophosphamide / Q000009:adverse effects* / Q000627:therapeutic use; D004890:Erythema / Q000139:chemically induced*; D005260:Female; D005533:Foot Dermatoses / Q000139:chemically induced*; D006229:Hand Dermatoses / Q000139:chemically induced*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy
D003520:Cyclophosphamide